Necyk Candace, Cor Ken, Mazzuca Arianna, Meleshko Lauren
Faculty of Pharmacy and Pharmaceutical Sciences (Necyk, Cor), University of Alberta, Edmonton, Alberta, Canada.
Alberta Health Services (Mazzuca), Edmonton, Alberta, Canada; Canada Safeway (Meleshko), Edmonton, Alberta, Canada.
Can Pharm J (Ott). 2019 Aug 13;152(6):376-387. doi: 10.1177/1715163519865914. eCollection 2019 Nov-Dec.
Pharmacists play an important role in managing patients with prescription drug abuse and addiction (PDAA). The objective of this study was to explore Alberta pharmacists' practices, views and confidence in the management of patients at risk of or living with PDAA in their practice setting.
A 26-question online questionnaire was distributed to 4261 pharmacists across Alberta, of whom 656 (15%) participated. The questionnaire consisted of 17 multiple-choice, 6 multipart and 3 free-response questions. Questionnaire responses were collected and analyzed in Qualtrics.
Sixty-six percent ( = 408) of pharmacists indicated that PDAA was prevalent in their practice setting, with 55% ( = 340) of respondents encountering more than 6 patients with suspected or known PDAA a month. Thirty-five percent ( = 198) of pharmacists indicated they were moderately confident at identifying patients with potential PDAA. However, 41% ( = 235) of the pharmacists indicated that they only discuss PDAA with identified patients less than half of the time. Pharmacists lacked confidence in their ability to discuss PDAA treatment options with their patients as well as collaborate with addiction treatment facilities. Lack of training or knowledge in PDAA (48%) and uncertainty of how to initiate discussion or effectively communicate with patients about PDAA (39%) were identified as barriers that significantly or very significantly hindered respondents from managing PDAA in their practice.
Although many pharmacists are moderately confident in identifying patients with potential PDAA, several barriers hinder intervention. Providing pharmacists with additional training and resources may better equip them to manage PDAA within their practice settings. 2019;152:xx-xx.
药剂师在管理处方药滥用和成瘾（PDAA）患者方面发挥着重要作用。本研究的目的是探讨艾伯塔省药剂师在其实践环境中对有PDAA风险或患有PDAA的患者进行管理的实践、观点和信心。
向艾伯塔省的4261名药剂师发放了一份包含26个问题的在线问卷，其中656名（15%）参与了调查。问卷由17个多项选择题、6个多部分问题和3个自由回答问题组成。问卷回复在Qualtrics中进行收集和分析。
66%（n = 408）的药剂师表示PDAA在他们的实践环境中很普遍，55%（n = 340）的受访者每月遇到6名以上疑似或已知患有PDAA的患者。35%（n = 198）的药剂师表示他们在识别潜在PDAA患者方面有一定信心。然而，41%（n = 235）的药剂师表示他们与已识别的患者讨论PDAA的时间不到一半。药剂师对与患者讨论PDAA治疗方案以及与成瘾治疗机构合作缺乏信心。48%的受访者认为缺乏PDAA方面的培训或知识以及39%的受访者不确定如何启动讨论或与患者有效沟通PDAA是在实践中显著或非常显著阻碍他们管理PDAA的障碍。
尽管许多药剂师在识别潜在PDAA患者方面有一定信心，但仍有几个障碍阻碍干预。为药剂师提供额外的培训和资源可能会更好地使他们在实践环境中管理PDAA。2019年；152:xx - xx。
